Advertisement
Advertisement
U.S. markets open in 2 hours 45 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Sona Nanotech Inc. (SNANF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0892+0.0172 (+23.89%)
At close: 01:10PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0720
Open0.0892
BidN/A x N/A
AskN/A x N/A
Day's Range0.0892 - 0.0892
52 Week Range0.0310 - 0.4310
Volume1,800
Avg. Volume4,466
Market Cap7.633M
Beta (5Y Monthly)-2.19
PE Ratio (TTM)N/A
EPS (TTM)-0.0920
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SNANF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SONA NANOTECH INC
    DXCM: Lowering target price to $117.00DEXCOM INC has an Investment Rating of HOLD; a target price of $117.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Newsfile

    Sona Signs MOU for Bovine TB Test Development and Commercialization

    This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021 Halifax, Nova Scotia--(Newsfile Corp. - November 8, 2022) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has entered into a memorandum of understanding ("MOU") to evaluate, and if determined effective, to commercialize its bovine tuberculosis ...

  • Newsfile

    Sona Announces Commercial Agreement with Siva Therapeutics

    This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021, to its short form base prospectus dated March 31, 2021.Halifax, Nova Scotia--(Newsfile Corp. - October 20, 2022) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has entered into an agreement to supply certain gold nanorod material to Siva Therapeutics, Inc. ("Siva"), a developer of ...

  • Newsfile

    Sona Provides Corporate Update

    This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021 Halifax, Nova Scotia--(Newsfile Corp. - May 19, 2022) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces the termination of its licensing agreement with Arlington Scientific for the Company's COVID-19 rapid saliva test following its analysis of data from two clinicial ...

Advertisement
Advertisement